Summit’s ivonescimab failed to deliver the survival extension needed for FDA review acceptance after the agency declined to overlook initial efficacy shortcomings in a form of lung cancer. The setback delays the company’s first U.S. approval push and adds uncertainty around timelines for subsequent regulatory engagements. The decision highlights the persistent challenge of demonstrating durable benefit for complex, multi-target oncology approaches in solid tumors, especially when early endpoints do not convincingly translate into survival improvements. For investors and partners, the rejection changes near-term expectations around clinical catalyst scheduling and may force renewed protocol refinement for later attempts—potentially reshaping how the asset competes against established checkpoint and combination standards.